Alternative Names:

Alpha-synuclein; NACP; non A-beta component of AD amyloid; PARK1; PARK4; PD1; SNCA;

Application:

WB IHC ICC/IF

Reactivity:

Human

Dilution:

WB 1:500~1:2000 IHC 1:50~1:200 ICC/IF 1:50~1:200

	Western blot analysis of Phospho-alpha Synuclein (Ser129) expression in (1) 293T cell lysate; (2) 293T cell lysate transfected with Polo-Like Kinase 2 and alpha Synuclein.

Purification:

Affinity-chromatography

Specificity:

Phospho-alpha Synuclein (S129) Antibody detects endogenous levels of total Phospho-alpha Synuclein (S129)

Immunogen:

A synthesized peptide derived from human Phospho-alpha Synuclein (S129)

Description:

SNCA a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson's disease. A major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced isoforms transcripts have been identified.

Storage Condition and Buffer:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle.